The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024
Global Phase-3 study initiation expected in the second half of 2024
Suven Life Sciences has reported total income of Rs. 9.43 crores during the period ended June 30, 2023
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
Subscribe To Our Newsletter & Stay Updated
